Daily Cardiology Research Analysis
A cluster randomized trial in Nature Medicine shows a telemedicine-based, village doctor–led integrated care model for atrial fibrillation improves adherence and reduces cardiovascular events in rural China. A randomized trial (SIBLINT-ISR) demonstrates sirolimus-coated balloons are noninferior to paclitaxel-coated balloons for coronary in-stent restenosis. A meta-analysis finds sodium-glucose cotransporter 2 inhibitors consistently reduce cardiorenal outcomes across races and regions, with stro
Summary
A cluster randomized trial in Nature Medicine shows a telemedicine-based, village doctor–led integrated care model for atrial fibrillation improves adherence and reduces cardiovascular events in rural China. A randomized trial (SIBLINT-ISR) demonstrates sirolimus-coated balloons are noninferior to paclitaxel-coated balloons for coronary in-stent restenosis. A meta-analysis finds sodium-glucose cotransporter 2 inhibitors consistently reduce cardiorenal outcomes across races and regions, with stronger heart failure hospitalization benefits in Black and Asian populations.
Research Themes
- Telemedicine-enabled integrated cardiovascular care
- Optimization of interventional and device-based therapies
- Health equity and generalizability of cardiometabolic treatments
Selected Articles
1. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial.
In a cluster randomized trial across 30 village clinics (n=1,039 older adults with AF), a telemedicine-based, village doctor–led integrated care model significantly increased adherence to AF care and reduced composite cardiovascular events versus usual care (HR 0.64, 95% CI 0.50–0.82). Benefits persisted over a median 34 months.
Impact: Demonstrates a scalable care-delivery innovation that improves outcomes for AF in resource-limited settings, addressing a major global implementation gap.
Clinical Implications: Health systems can deploy telemedicine-supported, community clinician–led AF integrated care pathways to improve adherence and reduce cardiovascular events, especially in rural or underserved areas.
Key Findings
- At 12 months, integrated AF care adherence was 33.1% with telemedicine vs 8.7% with usual care (between-group difference 24.4%, 95% CI 18.3–30.5; P<0.001).
- Over 34.0 months, the rate of composite cardiovascular events was lower with telemedicine (6.2%/year) than usual care (9.6%/year); HR 0.64 (95% CI 0.50–0.82; P<0.001).
- Sustained improvement in adherence at ~34 months: 41.8% vs 10.3% meeting integrated care criteria (P<0.001).
Methodological Strengths
- Cluster randomized design with pragmatic implementation in real-world rural clinics
- Clinically meaningful outcomes with blinded adjudication and prolonged follow-up
Limitations
- Single-country setting may limit generalizability to other health systems
- Potential contamination or variability in implementation across clusters
Future Directions: Evaluate cost-effectiveness, scalability across diverse health systems, and adaptation for other chronic cardiovascular conditions.
In rural China, where healthcare relies on village doctors (nonspecialized practitioners who work exclusively in their village clinics), delivering integrated atrial fibrillation (AF) management poses challenges. We developed a telemedicine-based, village doctor-led integrated care model and conducted a cluster randomized clinical trial to assess its efficacy compared to usual care. A total of 30 village clinics were randomly assigned (1:1) to the intervention or control group, with 1,039 village residents a
2. Sirolimus- vs Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis: The SIBLINT-ISR Randomized Trial.
In a 16-center, assessor-blinded randomized trial (n=258), a novel sirolimus-coated balloon was noninferior to a paclitaxel-coated balloon for coronary in-stent restenosis based on 9-month in-segment late lumen loss. Twelve-month clinical outcomes were similar between groups.
Impact: Head-to-head randomized evidence informs device selection for ISR, expanding therapeutic options with sirolimus-coated balloons.
Clinical Implications: Sirolimus-coated balloons can be considered an alternative to paclitaxel-coated balloons for ISR, with comparable angiographic efficacy and short-term clinical outcomes.
Key Findings
- Noninferiority achieved for 9-month in-segment late lumen loss: SCB 0.37 ± 0.48 mm vs PCB 0.30 ± 0.38 mm; difference 0.07 mm (95% CI −0.05 to 0.19), P for noninferiority < 0.0001.
- No significant differences in 12-month clinical outcomes between SCB and PCB.
- Multicenter (16 sites), assessor-blinded randomized design with 258 patients and 285 lesions.
Methodological Strengths
- Assessor-blinded randomized controlled design with prespecified noninferiority margin
- Multicenter enrollment increasing external validity
Limitations
- Sample size modest and powered for angiographic, not hard clinical endpoints
- Follow-up limited to 12 months for clinical outcomes
Future Directions: Longer-term follow-up and subgroup analyses (e.g., BMS vs DES ISR) to define durability and identify populations benefiting most from SCB.
BACKGROUND: The use of drug-coated balloons is a well-established strategy for the management of coronary vessels. However, head-to-head comparisons of sirolimus-coated balloons (SCBs) and paclitaxel-coated balloons (PCBs) for treating in-stent restenosis (ISR) are currently limited. OBJECTIVES: The aim of this randomized, controlled trial (SIBLINT-ISR [Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis]) was to compare a novel SCB with a PCB for the treatment of ISR. METHODS: In this prospective, assessor-blinded, controlled trial, patients with eligible ISR lesions were randomized 1:1 to treatment with either an SCB (SeQuent SCB, B. Braun Melsungen; 4 μg/mm RESULTS: A total of 258 patients with 285 lesions at 16 sites were randomly assigned to the SCB (n = 130) and PCB (n = 128) groups. At 9 months, the difference in the primary endpoint of in-segment LLL between the SCB group (0.37 ± 0.48 mm) and the PCB group (0.30 ± 0.38 mm) was 0.07 mm (95% CI: -0.05 to 0.19 mm), demonstrating noninferiority of the SCB to the PCB in terms of in-segment LLL, with a noninferiority margin of 0.20 mm (P for noninferiority < 0.0001). There were no significant differences in 12-month clinical outcomes between the SCB and PCB groups. CONCLUSIONS: In this study, a novel SCB was found to be noninferior to a PCB in terms of in-segment LLL at 9 months in treating patients with ISR. (Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis [SIBLINT ISR]; NCT04240444).
3. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis.
Across 14 RCTs (n=94,445), SGLT2 inhibitors consistently reduced cardiorenal outcomes across races and regions. Heart failure hospitalization benefits were more pronounced in Black patients (RHR 0.64 vs White) and in Asia (RHR 0.52 vs other regions), supporting broad use while highlighting differential effects.
Impact: Addresses generalizability and equity of a cornerstone cardiometabolic therapy, informing population-specific expectations and trial representation.
Clinical Implications: Clinicians can expect SGLT2 inhibitor benefits across diverse populations; greater HF hospitalization reduction may be anticipated in Black patients and Asian regions, underscoring the need for inclusive trial enrollment and tailored implementation.
Key Findings
- Meta-analysis of 14 RCTs (n=94,445) showed consistent efficacy of SGLT2 inhibitors across races and regions.
- HF hospitalization benefit more pronounced in Black patients vs White (RHR 0.64, 95% CI 0.44–0.94) and numerically in Asian patients (RHR 0.62, 95% CI 0.38–1.01).
- Regional analysis showed stronger HF hospitalization reduction in Asia (RHR 0.52, 95% CI 0.33–0.81).
Methodological Strengths
- Inclusion of large-scale randomized trials with prespecified subgroup analyses across race/region
- Use of ratio of hazard ratios enabling cross-group comparative effectiveness
Limitations
- Heterogeneity in trial designs and outcome definitions across included RCTs
- Subgroup analyses may be underpowered; potential residual confounding in race/region categorizations
Future Directions: Prospective studies powered for race/region interactions and mechanistic work to explain differential HF benefits.
BACKGROUND: To investigate the efficacy of SGLT2 inhibitors on multiple cardiorenal outcomes across different racial/ethnic groups and regions. METHODS: We searched PubMed, Cochrane Library, Web of Science, and Embase databases in April 2024 for a systematic review and meta-analysis. Owing to inconsistencies in the reporting of the racial/ethnic and regional demographics, participants were grouped into three racial groups (Asian, Black, and White) and four regional (Asia, Central/South America, Europe, North America) groups. We compared the efficacy of SGLT2 inhibitors among these racial/ethnic and regional groups by calculating the ratio of hazard ratios (RHR). We evaluated the composite of cardiovascular death or hospitalization for heart failure (HHF), cardiovascular death, HHF, all-cause death, major adverse cardiac events, and cardiorenal composite outcomes. RESULTS: We included 14 randomized placebo-controlled trials with 94,445 participants. Across the three racial/ethnic groups, SGLT2 inhibitors showed comparable efficacy. Compared with White patients, the efficacy of SGLT2 inhibitors on HHF was more pronounced in Black patients (RHR, 0.64; 95 % confidence interval [CI], 0.44-0.94), and a numerically lower risk was associated with Asian patients (RHR, 0.62; 95 % CI, 0.38-1.01). A consistent reduction in cardiovascular events with SGLT2 inhibitors was observed across all regions, while the efficacy of SGLT2 inhibitors on HHF was more pronounced in Asia than in other regions (RHR, 0.52; 95 % CI, 0.33-0.81). CONCLUSIONS: SGLT2 inhibitors showed generally consistent efficacy across various racial/ethnic and regional groups, with some differences noted in specific populations. Ensuring adequate representation of diverse populations in clinical trials would be key to addressing healthcare disparities.